Atara Biotherapeutics, Inc.
ATRA
$15.54
$1.5611.16%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 17.58M | 98.15M | 32.75M | 40.19M | 28.64M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 17.58M | 98.15M | 32.75M | 40.19M | 28.64M |
| Cost of Revenue | 554.00K | 39.52M | 35.52M | 51.53M | 4.63M |
| Gross Profit | 17.02M | 58.63M | -2.76M | -11.34M | 24.01M |
| SG&A Expenses | 5.94M | 10.01M | 9.44M | 10.42M | 8.91M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.86M | 49.53M | 44.96M | 61.95M | 46.52M |
| Operating Income | 4.72M | 48.62M | -12.20M | -21.76M | -17.88M |
| Income Before Tax | 2.39M | 38.01M | -12.71M | -21.93M | -19.05M |
| Income Tax Expenses | 3.00K | -- | -19.00K | -17.00K | -- |
| Earnings from Continuing Operations | 2.39M | 38.01M | -12.69M | -21.91M | -19.05M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.39M | 38.01M | -12.69M | -21.91M | -19.05M |
| EBIT | 4.72M | 48.62M | -12.20M | -21.76M | -17.88M |
| EBITDA | 5.62M | 50.41M | -11.10M | -20.53M | -17.03M |
| EPS Basic | 0.20 | 3.53 | -1.19 | -2.93 | -3.10 |
| Normalized Basic EPS | 0.20 | 2.78 | -0.74 | -1.84 | -1.90 |
| EPS Diluted | 0.19 | 3.50 | -1.19 | -2.93 | -3.10 |
| Normalized Diluted EPS | 0.20 | 2.75 | -0.74 | -1.84 | -1.90 |
| Average Basic Shares Outstanding | 12.20M | 10.76M | 10.71M | 7.47M | 6.14M |
| Average Diluted Shares Outstanding | 12.31M | 10.85M | 10.71M | 7.47M | 6.14M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |